{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:26:58Z","timestamp":1790746018363,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s13555-025-01384-4","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T22:48:38Z","timestamp":1743893318000},"page":"1181-1193","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Health-Related Quality of Life in Chronic Hand Eczema in a Phase\u00a02b Trial of Delgocitinib Cream"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct03683719","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3139-129X","authenticated-orcid":false,"given":"Timo","family":"Buhl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D.","family":"Ehst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Thyssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Hahn-Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berith Fredsted","family":"Hagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eydna D.","family":"Apol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tove","family":"Agner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,5]]},"reference":[{"key":"1384_CR1","unstructured":"Buhl T, Bauer A, Thyssen JP, Hahn-Pedersen J, Hagen BF, Agner T. Treatment with delgocitinib cream improves health-related quality of life in patients with chronic hand eczema. In: 15th congress of the European Society of Contact Dermatitis (ESCD), 8\u201310 June 2022. Amsterdam, the Netherlands: Contact Dermatitis; 2022."},{"issue":"4","key":"1384_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/j.1600-0536.2007.01179.x","volume":"57","author":"TL Diepgen","year":"2007","unstructured":"Diepgen TL, Agner T, Aberer W, et al. Management of chronic hand eczema. Contact Dermatitis. 2007;57(4):203\u201310.","journal-title":"Contact Dermatitis"},{"issue":"3","key":"1384_CR3","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/DER.0000000000000598","volume":"31","author":"S Capucci","year":"2020","unstructured":"Capucci S, Hahn-Pedersen J, Vilsboll A, Kragh N. Impact of atopic dermatitis and chronic hand eczema on quality of life compared with other chronic diseases. Dermatitis. 2020;31(3):178\u201384.","journal-title":"Dermatitis"},{"key":"1384_CR4","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.2147\/TCRM.S292504","volume":"16","author":"C Dubin","year":"2020","unstructured":"Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the treatment of chronic hand eczema: successes and key challenges. Ther Clin Risk Manag. 2020;16:1319\u201332.","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"1384_CR5","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/cod.14035","volume":"86","author":"JP Thyssen","year":"2022","unstructured":"Thyssen JP, Schuttelaar MLA, Alfonso JH, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis. 2022;86(5):357\u201378.","journal-title":"Contact Dermatitis"},{"issue":"6","key":"1384_CR6","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/cod.12973","volume":"78","author":"SE Marron","year":"2018","unstructured":"Marron SE, Tomas-Aragones L, Navarro-Lopez J, et al. The psychosocial burden of hand eczema: data from a European dermatological multicentre study. Contact Dermatitis. 2018;78(6):406\u201312.","journal-title":"Contact Dermatitis"},{"issue":"Suppl 1","key":"1384_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/jdv.16061","volume":"34","author":"T Agner","year":"2020","unstructured":"Agner T, Elsner P. Hand eczema: epidemiology, prognosis and prevention. J Eur Acad Dermatol Venereol. 2020;34(Suppl 1):4\u201312.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1384_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ad.2019.04.005","volume":"111","author":"JF Silvestre Salvador","year":"2020","unstructured":"Silvestre Salvador JF, Heras Mendaza F, Hervella Garc\u00e9s M, et al. Guidelines for the diagnosis, treatment, and prevention of hand eczema. Actas Dermosifiliogr (Engl Ed). 2020;111(1):26\u201340.","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"2","key":"1384_CR9","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s12325-019-01164-5","volume":"37","author":"L Grant","year":"2020","unstructured":"Grant L, Seiding Larsen L, Burrows K, et al. Development of a conceptual model of chronic hand eczema (CHE) based on qualitative interviews with patients and expert dermatologists. Adv Ther. 2020;37(2):692\u2013706.","journal-title":"Adv Ther"},{"issue":"2","key":"1384_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2340\/00015555-1632","volume":"94","author":"C Apfelbacher","year":"2014","unstructured":"Apfelbacher C, Molin S, Weisshaar E, et al. Characteristics and provision of care in patients with chronic hand eczema: updated data from the CARPE registry. Acta Derm Venereol. 2014;94(2):163\u20137.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"1384_CR11","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s40271-019-00373-y","volume":"12","author":"A Barrett","year":"2019","unstructured":"Barrett A, Hahn-Pedersen J, Kragh N, Evans E, Gnanasakthy A. Patient-reported outcome measures in atopic dermatitis and chronic hand eczema in adults. Patient. 2019;12(5):445\u201359.","journal-title":"Patient"},{"issue":"4","key":"1384_CR12","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/jdv.13479","volume":"30","author":"S Cazzaniga","year":"2016","unstructured":"Cazzaniga S, Ballmer-Weber BK, Gr\u00e4ni N, et al. Medical, psychological and socio-economic implications of chronic hand eczema: a cross-sectional study. J Eur Acad Dermatol Venereol. 2016;30(4):628\u201337.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1384_CR13","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/cod.14066","volume":"86","author":"MJ Brands","year":"2022","unstructured":"Brands MJ, Loman L, Schuttelaar MLA. Exposure and work-related factors in subjects with hand eczema: data from a cross-sectional questionnaire within the lifelines cohort study. Contact Dermatitis. 2022;86(6):493\u2013506.","journal-title":"Contact Dermatitis"},{"issue":"6","key":"1384_CR14","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1111\/bjd.12275","volume":"168","author":"B Meding","year":"2013","unstructured":"Meding B, Lindahl G, Alderling M, Wrangsjo K, Anveden BI. Is skin exposure to water mainly occupational or nonoccupational? A population-based study. Br J Dermatol. 2013;168(6):1281\u20136.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1384_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.det.2011.11.002","volume":"30","author":"MK Basra","year":"2012","unstructured":"Basra MK, Chowdhury MM, Smith EV, Freemantle N, Piguet V. A review of the use of the Dermatology Life Quality Index as a criterion in clinical guidelines and health technology assessments in psoriasis and chronic hand eczema. Dermatol Clin. 2012;30(2):237\u201344, viii.","journal-title":"Dermatol Clin"},{"issue":"2","key":"1384_CR16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40271-016-0196-6","volume":"10","author":"C Copley-Merriman","year":"2017","unstructured":"Copley-Merriman C, Zelt S, Clark M, Gnanasakthy A. Impact of measuring patient-reported outcomes in dermatology drug development. Patient. 2017;10(2):203\u201313.","journal-title":"Patient"},{"key":"1384_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdin.2023.11.004","volume":"14","author":"A Egeberg","year":"2024","unstructured":"Egeberg A, Schlapbach C, Haugaard JH, et al. Adverse events from topical corticosteroid use in chronic hand eczema\u2014findings from the Danish Skin Cohort. JAAD Int. 2024;14:77\u201383.","journal-title":"JAAD Int"},{"issue":"3","key":"1384_CR18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/cod.14135","volume":"87","author":"SV Svendsen","year":"2022","unstructured":"Svendsen SV, Bach RO, Mortz CG. Prevalence of contact allergy to corticosteroids in a Danish patient population. Contact Dermatitis. 2022;87(3):273\u20139.","journal-title":"Contact Dermatitis"},{"issue":"5","key":"1384_CR19","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000484407","volume":"233","author":"U Nygaard","year":"2017","unstructured":"Nygaard U, Deleuran M, Vestergaard C. Emerging treatment options in atopic dermatitis: topical therapies. Dermatology. 2017;233(5):333\u201343.","journal-title":"Dermatology"},{"issue":"4","key":"1384_CR20","first-page":"CD004055","volume":"4","author":"WA Christoffers","year":"2019","unstructured":"Christoffers WA, Coenraads PJ, Svensson \u00c5, et al. Interventions for hand eczema. Cochrane Database Syst Rev. 2019;4(4):CD004055.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"1384_CR21","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jaci.2015.03.051","volume":"136","author":"W Amano","year":"2015","unstructured":"Amano W, Nakajima S, Kunugi H, et al. The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling. J Allergy Clin Immunol. 2015;136(3):667-77.e7.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1384_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/exd.13370","volume":"27","author":"A Tanimoto","year":"2018","unstructured":"Tanimoto A, Shinozaki Y, Yamamoto Y, et al. A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: comparison with conventional therapeutic agents. Exp Dermatol. 2018;27(1):22\u20139.","journal-title":"Exp Dermatol"},{"issue":"1","key":"1384_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00011-014-0782-9","volume":"64","author":"A Tanimoto","year":"2015","unstructured":"Tanimoto A, Ogawa Y, Oki C, et al. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm Res. 2015;64(1):41\u201351.","journal-title":"Inflamm Res"},{"issue":"5","key":"1384_CR24","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/bjd.18469","volume":"182","author":"M Worm","year":"2020","unstructured":"Worm M, Bauer A, Elsner P, Mahler V, Molin S, Nielsen TSS. Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase\u00a0IIa study. Br J Dermatol. 2020;182(5):1103\u201310.","journal-title":"Br J Dermatol"},{"issue":"10451","key":"1384_CR25","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(24)01027-4","volume":"404","author":"R Bissonnette","year":"2024","unstructured":"Bissonnette R, Warren RB, Pinter A, et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase\u00a03 trials. Lancet. 2024;404(10451):461\u201373.","journal-title":"Lancet"},{"key":"1384_CR26","unstructured":"Anzupgo 20\u00a0mg\/g cream [summary of product characteristics] 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/anzupgo-epar-product-information_en.pdf."},{"issue":"1","key":"1384_CR27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/bjd.21037","volume":"187","author":"M Worm","year":"2022","unstructured":"Worm M, Thyssen JP, Schliemann S, et al. The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase\u00a0IIb trial. Br J Dermatol. 2022;187(1):42\u201351.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1384_CR28","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jaad.2005.11.1053","volume":"54","author":"JF Fowler","year":"2006","unstructured":"Fowler JF, Ghosh A, Sung J, et al. Impact of chronic hand dermatitis on quality of life, work productivity, activity impairment, and medical costs. J Am Acad Dermatol. 2006;54(3):448\u201357.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1384_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1600-0536.2008.01362.x","volume":"59","author":"T Agner","year":"2008","unstructured":"Agner T, Andersen KE, Brandao FM, et al. Hand eczema severity and quality of life: a cross-sectional, multicentre study of hand eczema patients. Contact Dermatitis. 2008;59(1):43\u20137.","journal-title":"Contact Dermatitis"},{"issue":"2","key":"1384_CR30","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/j.0105-1873.2006.00783.x","volume":"54","author":"RS Cvetkovski","year":"2006","unstructured":"Cvetkovski RS, Zachariae R, Jensen H, Olsen J, Johansen JD, Agner T. Quality of life and depression in a population of occupational hand eczema patients. Contact Dermatitis. 2006;54(2):106\u201311.","journal-title":"Contact Dermatitis"},{"issue":"12","key":"1384_CR31","doi-asserted-by":"publisher","first-page":"A459","DOI":"10.1016\/S1098-3015(10)75274-8","volume":"7","author":"N Freemantle","year":"2009","unstructured":"Freemantle N, Aldridge R, Stanley G. PSS37 Quality of life in chronic hand eczema as measured by the Dermatology Life Quality Index. Value in Health. 2009;7(12):A459.","journal-title":"Value in Health"},{"issue":"3","key":"1384_CR32","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s13555-024-01114-2","volume":"14","author":"S Molin","year":"2024","unstructured":"Molin S, Larsen LS, Joensson P, et al. Development and psychometric validation of a patient-reported outcome measure to assess the signs and symptoms of chronic hand eczema: the Hand Eczema Symptom Diary (HESD). Dermatol Ther (Heidelb). 2024;14(3):643\u201369.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1384_CR33","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/cod.14303","volume":"89","author":"A Bauer","year":"2023","unstructured":"Bauer A, Thyssen JP, Buhl T, et al. Treatment with delgocitinib cream improves itch, pain and other signs and symptoms of chronic hand eczema: results from the Hand Eczema Symptom Diary in a phase\u00a0IIb randomized clinical trial. Contact Dermatitis. 2023;89(1):46\u201353.","journal-title":"Contact Dermatitis"},{"issue":"3","key":"1384_CR34","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"1384_CR35","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","volume":"125","author":"Y Hongbo","year":"2005","unstructured":"Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Investig Dermatol. 2005;125(4):659\u201364.","journal-title":"J Investig Dermatol"},{"key":"1384_CR36","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s10198-003-0182-5","volume":"4","author":"W Greiner","year":"2003","unstructured":"Greiner W, Weijnen T, Nieuwenhuizen M, et al. A single European currency for EQ-5D health states: results from a six-country study. Eur J Health Econ HEPAC. 2003;4:222\u201331.","journal-title":"Eur J Health Econ HEPAC"},{"key":"1384_CR37","unstructured":"EuroQol Research Foundation. EQ-5D-5L user guide: basic information on how to use the EQ-5D-5L instrument, version 3.0 Rotterdam EuroQol Research Foundation; 2019. https:\/\/euroqol.org\/publications\/user-guides\/"},{"issue":"5","key":"1384_CR38","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B van Hout","year":"2012","unstructured":"van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708\u201315.","journal-title":"Value Health"},{"key":"1384_CR39","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s11136-020-02688-y","volume":"30","author":"Y-S Feng","year":"2021","unstructured":"Feng Y-S, Kohlmann T, Janssen MF, Buchholz I. Psychometric properties of the EQ-5D-5L: a systematic review of the literature. Qual Life Res. 2021;30:647\u201373.","journal-title":"Qual Life Res"},{"key":"1384_CR40","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1007\/s13555-024-01267-0","volume":"14","author":"E Weisshaar","year":"2024","unstructured":"Weisshaar E, Yuksel YT, Agner T, et al. Development and validation of a patient-reported outcome measure of the impact of chronic hand eczema on health-related quality of life: the Hand Eczema Impact Scale (HEIS). Dermatol Ther (Heidelb). 2024;14:3047\u201370.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"1384_CR41","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s00403-024-02818-3","volume":"316","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Agner T, Baranowski K, et al. Validation of the Investigator Global Assessment of Chronic Hand Eczema (IGA-CHE): a new clinician reported outcome measure of CHE severity. Arch Dermatol Res. 2024;316(4):110.","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"1384_CR42","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/j.1365-2133.2008.08487.x","volume":"158","author":"T Ruzicka","year":"2008","unstructured":"Ruzicka T, Lynde C, Jemec G, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol. 2008;158(4):808\u201317.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1384_CR43","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/cod.12130","volume":"70","author":"PA Cortesi","year":"2014","unstructured":"Cortesi PA, Scalone L, Belisari A, et al. Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. Contact Dermatitis. 2014;70(3):158\u201368.","journal-title":"Contact Dermatitis"},{"issue":"11","key":"1384_CR44","first-page":"19","volume":"8","author":"D Dibenedetti","year":"2015","unstructured":"Dibenedetti D, Baranowski E, Zelt S, Reynolds M, Sherrill B. Assessing United States patient and dermatologist experiences with severe chronic hand eczema. J Clin Aesth Dermatol. 2015;8(11):19\u201327.","journal-title":"J Clin Aesth Dermatol"},{"issue":"6","key":"1384_CR45","doi-asserted-by":"publisher","first-page":"749","DOI":"10.2340\/00015555-1584","volume":"93","author":"YC Chen","year":"2013","unstructured":"Chen YC, Wu CS, Lu YW, et al. Atopic dermatitis and non-atopic hand eczema have similar negative impacts on quality of life: implications for clinical significance. Acta Derm Venereol. 2013;93(6):749\u201350.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"1384_CR46","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1365-2133.2009.09099.x","volume":"161","author":"C Moberg","year":"2009","unstructured":"Moberg C, Alderling M, Meding B. Hand eczema and quality of life: a population-based study. Br J Dermatol. 2009;161(2):397\u2013403.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1384_CR47","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1007\/s11136-023-03411-3","volume":"32","author":"M \u00c5str\u00f6m","year":"2023","unstructured":"\u00c5str\u00f6m M, Thet Lwin ZM, Teni FS, Burstr\u00f6m K, Berg J. Use of the visual analogue scale for health state valuation: a scoping review. Qual Life Res. 2023;32(10):2719\u201329.","journal-title":"Qual Life Res"},{"issue":"1","key":"1384_CR48","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/cod.12206","volume":"71","author":"A Mollerup","year":"2014","unstructured":"Mollerup A, Veien NK, Johansen JD. An analysis of gender differences in patients with hand eczema\u2014everyday exposures, severity, and consequences. Contact Dermatitis. 2014;71(1):21\u201330.","journal-title":"Contact Dermatitis"},{"issue":"1","key":"1384_CR49","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000365390","volume":"230","author":"MK Basra","year":"2015","unstructured":"Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230(1):27\u201333.","journal-title":"Dermatology"},{"issue":"2","key":"1384_CR50","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s13555-017-0181-6","volume":"7","author":"EL Simpson","year":"2017","unstructured":"Simpson EL. Dupilumab improves general health-related quality-of-life in patients with moderate-to-severe atopic dermatitis: pooled results from two randomized, controlled phase\u00a03 clinical trials. Dermatol Ther (Heidelb). 2017;7(2):243\u20138.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"1384_CR51","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/bjd.12819","volume":"171","author":"RF Ofenloch","year":"2014","unstructured":"Ofenloch RF, Weisshaar E, Dumke AK, Molin S, Diepgen TL, Apfelbacher C. The Quality of Life in Hand Eczema Questionnaire (QOLHEQ): validation of the German version of a new disease-specific measure of quality of life for patients with hand eczema. Br J Dermatol. 2014;171(2):304\u201312.","journal-title":"Br J Dermatol"},{"key":"1384_CR52","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1017\/S0266462308081063","volume":"24","author":"MF Drummond","year":"2008","unstructured":"Drummond MF, Schwartz JS, J\u00f6nsson B, et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care. 2008;24:367\u20138.","journal-title":"Int J Technol Assess Health Care"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01384-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01384-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01384-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T18:02:32Z","timestamp":1745690552000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01384-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,5]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1384"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01384-4","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,5]]},"assertion":[{"value":"11 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Timo Buhl has been a speaker\/investigator\/advisor for AbbVie, ALK, Almirall, AstraZeneca, Bencard, Eli Lilly, Incyte, Galderma, Janssen, Kiniksa Pharmaceuticals, LEO Pharma, Novartis, R-Biopharm, Sanofi and ThermoFisher. Andrea Bauer has been a speaker\/advisor\/investigator and\/or received research funding from AbbVie, Almirall, Amgen, AstraZeneca, Biofrontera, Bristol-Myers Squibb, Celldex, Eli Lilly, Escient, Galderma, Genentech, Gilead, Incyte, Janssen, Jasper, LEO Pharma, L\u2019Or\u00e9al, Novartis, Pfizer, Pharvaris, Sanofi\/Regeneron and Shire\/Takeda. Benjamin D. Ehst has been a speaker\/advisor\/investigator and\/or received research funding from AbbVie, Acelyrin, Aclaris, Allakos, Almirall, Alumis, Amgen, AnaptysBio, Arcutis, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Concert Pharma, Dermavant Sciences, Eli Lilly, Evelo Biosciences, Evommune, Incyte, Janssen, Kymab, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, Takeda, UCB Pharma and Ventyx. Julie Hahn-Pedersen was an employee of LEO Pharma A\/S, Ballerup, Denmark at the time of the study and is currently employed by Novo Nordisk A\/S. Berith Fredsted Hagen was an employee of LEO Pharma A\/S, Ballerup, Denmark at the time of the study and is currently employed by Zealand Pharma. Jacob P. Thyssen was an employee at the Department of Dermatology and Venereology, Bispebjerg Hospital, University of Copenhagen, Denmark at the time of the study and is currently employed at LEO Pharma A\/S, Ballerup, Denmark. Eydna D. Apol is an employee at LEO Pharma A\/S, Ballerup, Denmark. Tove Agner has been a speaker\/investigator\/advisor for AbbVie, Almirall, Eli Lilly, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The trial was conducted in accordance with the Helsinki Declaration of 1964 and its later amendments, Good Clinical Practice guidelines, and applicable regulatory requirements, and was approved by the Regional Committees on Health Research Ethics for Capital Region of Denmark (reference number 18047858), and independent ethics committees or institutional review boards for each study site (supplementary material). All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}